ATE518845T1 - Optische isomere eines iloperidon-metaboliten - Google Patents

Optische isomere eines iloperidon-metaboliten

Info

Publication number: ATE518845T1
Authority: AT; Austria
Prior art keywords: optical isomers; iloperidone metabolite; fouoro; isoxazol; piperidin
Prior art date: 2001-08-31

Application number

AT02767454T

Other languages

English (en)

Inventor

Dominique Grimler

Hans Kalkman

Hequn Yin

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-31

Filing date

2002-08-30

Publication date

2011-08-15

2002-08-30 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2011-08-15 Application granted granted Critical

2011-08-15 Publication of ATE518845T1 publication Critical patent/ATE518845T1/de

Links

XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
230000003287 optical effect Effects 0.000 title 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicinal Preparation (AREA)

AT02767454T 2001-08-31 2002-08-30 Optische isomere eines iloperidon-metaboliten ATE518845T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31639001P	2001-08-31	2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en)	2001-08-31	2002-08-30	Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number	Publication Date
ATE518845T1 true ATE518845T1 (de)	2011-08-15

Family

ID=23228843

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02767454T ATE518845T1 (de)	2001-08-31	2002-08-30	Optische isomere eines iloperidon-metaboliten

Country Status (9)

Country	Link
US (4)	US20050020632A1 (de)
EP (2)	EP2305656B1 (de)
JP (6)	JP2005504783A (de)
AT (1)	ATE518845T1 (de)
CY (2)	CY1112039T1 (de)
DK (2)	DK2305656T3 (de)
ES (2)	ES2398434T3 (de)
PT (2)	PT2305656E (de)
WO (1)	WO2003020707A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2358416T3 (es)	2001-10-30	2011-05-10	Novartis Ag	Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
SI1497266T1 (sl)	2002-03-27	2008-10-31	Glaxo Group Ltd	Derivati kinolina in njihova uporaba kot ligandi 5-ht6
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
EP1558582B1 (de)	2003-07-22	2005-12-21	Arena Pharmaceuticals, Inc.	Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
GB0322994D0 (en) *	2003-10-01	2003-11-05	Novartis Ag	Organic compounds
EP1799865B1 (de)	2004-09-30	2012-06-06	Vanda Pharmaceuticals Inc.	Verfahren für die verabreichung von iloperidone
US20100063093A1 (en)	2007-03-28	2010-03-11	Curt Wolfgang	Methods for the administration of iloperidone
US20070262395A1 (en)	2006-05-11	2007-11-15	Gibbons Jasper S	Memory cell access devices and methods of making the same
US8008144B2 (en)	2006-05-11	2011-08-30	Micron Technology, Inc.	Dual work function recessed access device and methods of forming
US20090306137A1 (en)	2006-05-22	2009-12-10	Wolfgang Curt D	Treatment for depressive disorders
WO2008121899A2 (en)	2007-03-29	2008-10-09	Vanda Pharmaceuticals Inc.	Method of predicting a predisposition to qt prolongation
US20150259747A1 (en)	2007-03-29	2015-09-17	Vanda Pharmaceuticals Inc.	Method of predicting a predisposition to qt prolongation
WO2008128166A1 (en) *	2007-04-13	2008-10-23	Concert Pharmaceuticals Inc.	Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
EP3075865B1 (de)	2007-05-18	2018-05-09	Vanda Pharmaceuticals Inc.	Genetische marker für die wirkung von iloperidon bei der behandlung psychotischer symptome
US8652776B2 (en)	2007-09-10	2014-02-18	Vanda Pharmaceuticals, Inc.	Prediction of QT prolongation based on SNP genotype
EP2254564A1 (de)	2007-12-12	2010-12-01	Glaxo Group Limited	Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
CA2709104C (en)	2007-12-13	2017-06-13	Vanda Pharmaceuticals Inc.	Method and composition for treating a serotonin receptor-mediated condition
US8729100B2 (en)	2007-12-13	2014-05-20	Vanda Pharmaceuticals, Inc.	Method and composition for treating an alpha adrenoceptor-mediated condition
US20110061014A1 (en)	2008-02-01	2011-03-10	Energyhub	Interfacing to resource consumption management devices
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US7824986B2 (en)	2008-11-05	2010-11-02	Micron Technology, Inc.	Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
JP5881597B2 (ja)	2009-04-06	2016-03-09	ヴァンダファーマシューティカルズインコーポレイテッド	Ｑｔ延長に対する素因を予測する方法
EP2416779B1 (de)	2009-04-06	2016-03-09	Vanda Pharmaceuticals Inc.	Verfahren zur vorhersagen der veranlagung zur qt verlängerung basierend auf bai3 gensequenz oder produkte davon
ES2604102T3 (es)	2009-04-06	2017-03-03	Vanda Pharmaceuticals Inc.	Método de tratamiento basado en polimorfismos del gen KCNQ1
WO2010117941A1 (en)	2009-04-06	2010-10-14	Vanda Pharmaceuticals, Inc.	Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
BR112012015084A2 (pt)	2009-12-23	2017-03-07	Lupin Ltd	composição farmacêutica de liberação lenta de iloperidone
US9000221B2 (en)	2010-09-07	2015-04-07	Symed Labs Limited	Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en)	2010-11-12	2012-05-18	Cadila Healthcare Limited	Process for preparing iloperidone
CA2865845C (en)	2012-03-14	2020-02-18	Vanda Pharmaceuticals Inc.	An iloperidone metabolite for use in the treatment of psychiatric disorders
CA2976383C (en)	2015-02-17	2023-05-23	Vanda Pharmaceuticals Inc.	Iloperidone for the treatment of schizophrenia
HK1245660A1 (zh)	2015-06-12	2018-08-31	Axovant Sciences Gmbh	有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en)	2015-07-15	2017-01-19	Axovant Sciences Ltd.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN114941015B (zh) *	2019-02-21	2024-05-03	深圳艾欣达伟医药科技有限公司	制造高镜像选择性二级醇的方法
US11607408B2 (en)	2019-10-15	2023-03-21	Vanda Pharmaceuticals Inc.	Method of treatment of schizophrenia
WO2023201182A1 (en)	2022-04-13	2023-10-19	Vanda Pharmaceuticals Inc.	Treatment of parkinson's disease and parkinson's disease psychosis
WO2024137439A1 (en)	2022-12-19	2024-06-27	Vanda Pharmaceuticals Inc.	Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
KR20260019503A (ko)	2023-06-02	2026-02-10	반다 파마슈티칼즈, 인코퍼레이티드.	일로페리돈을 사용한 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4804663A (en) *	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) *	1988-11-07	1992-10-27	Janssen Pharmaceutica N.V.	3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) *	1989-05-19	1994-11-15	Hoechst-Roussel Pharmaceuticals, Inc.	Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en)	1989-05-19	1998-07-07	Hoechst Marion Roussel, Inc.	3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) *	1989-05-19	1995-11-01	Hoechst Roussel Pharma	N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JPH05286868A (ja)	1992-04-03	1993-11-02	Kiyoshi Okawa	制がん剤複合体およびそのスクリーニング法
US5889006A (en) *	1995-02-23	1999-03-30	Schering Corporation	Muscarinic antagonists
US6172099B1 (en) *	1997-07-03	2001-01-09	Asahi Kasei Kogyo Kabushiki Kaisha	Tricyclic compounds having saturated rings and medicinal compositions containing the same
EP1551393A4 (de)	2002-07-30	2010-06-16	Peter Migaly	Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen

2002
- 2002-08-30 ES ES10009915T patent/ES2398434T3/es not_active Expired - Lifetime
- 2002-08-30 PT PT100099159T patent/PT2305656E/pt unknown
- 2002-08-30 US US10/488,128 patent/US20050020632A1/en not_active Abandoned
- 2002-08-30 DK DK10009915.9T patent/DK2305656T3/da active
- 2002-08-30 ES ES02767454T patent/ES2370634T3/es not_active Expired - Lifetime
- 2002-08-30 JP JP2003524978A patent/JP2005504783A/ja not_active Withdrawn
- 2002-08-30 EP EP10009915A patent/EP2305656B1/de not_active Expired - Lifetime
- 2002-08-30 AT AT02767454T patent/ATE518845T1/de active
- 2002-08-30 EP EP02767454A patent/EP1425272B1/de not_active Expired - Lifetime
- 2002-08-30 DK DK02767454.8T patent/DK1425272T3/da active
- 2002-08-30 WO PCT/EP2002/009700 patent/WO2003020707A1/en not_active Ceased
- 2002-08-30 PT PT02767454T patent/PT1425272E/pt unknown
2009
- 2009-03-13 US US12/403,755 patent/US7977356B2/en not_active Expired - Lifetime
- 2009-12-11 JP JP2009281094A patent/JP2010100633A/ja not_active Withdrawn
2011
- 2011-04-28 US US13/096,015 patent/US8314129B2/en not_active Expired - Lifetime
- 2011-11-02 CY CY20111101053T patent/CY1112039T1/el unknown
2012
- 2012-10-26 US US13/661,609 patent/US20130296366A1/en not_active Abandoned
2013
- 2013-01-23 CY CY20131100058T patent/CY1113550T1/el unknown
- 2013-01-31 JP JP2013017050A patent/JP2013116905A/ja not_active Withdrawn
- 2013-07-08 JP JP2013142873A patent/JP2013227335A/ja active Pending
2015
- 2015-08-06 JP JP2015156358A patent/JP2015227368A/ja active Pending
- 2015-08-06 JP JP2015156359A patent/JP2015214577A/ja active Pending

Also Published As

Publication number	Publication date
US8314129B2 (en)	2012-11-20
DK2305656T3 (da)	2013-02-11
HK1156309A1 (en)	2012-09-07
WO2003020707A1 (en)	2003-03-13
ES2398434T8 (es)	2017-10-09
JP2013116905A (ja)	2013-06-13
HK1066536A1 (en)	2005-03-24
PT2305656E (pt)	2013-01-10
US20110201646A1 (en)	2011-08-18
EP2305656B1 (de)	2012-10-24
JP2005504783A (ja)	2005-02-17
DK1425272T3 (da)	2011-11-21
CY1112039T1 (el)	2015-11-04
ES2370634T3 (es)	2011-12-21
JP2015227368A (ja)	2015-12-17
ES2398434T3 (es)	2013-03-19
EP2305656A1 (de)	2011-04-06
US20130296366A1 (en)	2013-11-07
CY1113550T1 (el)	2016-06-22
US7977356B2 (en)	2011-07-12
JP2015214577A (ja)	2015-12-03
US20050020632A1 (en)	2005-01-27
US20090176739A1 (en)	2009-07-09
JP2013227335A (ja)	2013-11-07
JP2010100633A (ja)	2010-05-06
EP1425272A1 (de)	2004-06-09
EP1425272B1 (de)	2011-08-03
PT1425272E (pt)	2011-10-19

Legal Events

Date

Code

Title

Description

2012-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1425272

Country of ref document: EP

Publication	Publication Date	Title
DK1425272T3 (da)	2011-11-21	Optiske isomerer af en iloperidon-metabolit
PE20080360A1 (es)	2008-05-22	Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
JP2010519243A5 (de)	2011-03-10
NO20076498L (no)	2008-02-20	Derivater av 4-(2-amino-1-hydroksyetyl)fenol som agonister av den betta2-adrenerge reseptoren
NO20051965D0 (no)	2005-04-22	Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
DE502004009532D1 (de)	2009-07-09	Fungizide ternäre wirkstoffkombinationen
NO20062370L (no)	2006-07-18	Amidderivater
NO341632B1 (no)	2017-12-11	Ny polymorf form av 5-klor-N({(5S)-2-okso-3[4-(3-okso-4-morfolinyl)-fenyl]-1,3-oksazolidin-5-yl}-metyl)-2-tiofenkarboksamid
JP2005504783A5 (de)	2009-08-27
ATE512961T1 (de)	2011-07-15	Amorphes nebivolol hydrochlorid und seine herstellung
RU2010134361A (ru)	2012-02-27	Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа
ATE544756T1 (de)	2012-02-15	Substituierte carbinolverbindungen
HRP20080446T3 (en)	2008-10-31	Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine
PE20091431A1 (es)	2009-10-19	Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
NO20065327L (no)	2006-12-18	Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
AR049699A1 (es)	2006-08-30	Derivados de pirimidina
JP2010143943A5 (de)	2012-01-05
BRPI0411603A (pt)	2006-08-08	4-(aminometil)-piperidina benzamidas como antagonistas 5ht4
NO20070974L (no)	2007-03-02	Substituerte N-acyl-2-aminotiazoler
JP2013510155A5 (de)	2013-12-19
DE602004009079D1 (de)	2007-10-31	Carbostyril-derivative zur beschleunigten speichelabsonderung
RU2503674C2 (ru)	2014-01-10	Замещенные производные сульфонамида
NO20051089L (no)	2005-05-02	Bredspektrede 2-amino-benzotiazol-sulfonamid-HIV-proteaseinhibitorer
NO20070972L (no)	2007-02-28	Benzyloksyderivater som MAOB-inhibitorer
ATE406363T1 (de)	2008-09-15	Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten